The American Cancer Society Cancer Action Network (ACS CAN) has released a report detailing the barriers to patient enrollment in therapeutic clinical trials for cancer. In its report, ACS CAN compiles all relevant evidence for clinical trial barriers in one place and discusses them in relation to each other, addressing each component’s contribution to the problem as a whole. ACS CAN also provides a complementary set of 23 recommendations for overcoming clinical trial barriers in numerous areas, including provider and institutional barriers, patient barriers, trial-design barriers, and disparities.
Posted 4/11/2018
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
